Andrew John Partridge - 09 Feb 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc.

Role
EVP & Chief Commercial Officer
Signature
/s/ Paolo Tombesi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
09 Feb 2022
Net transactions value
-$8,022
Form type
4
Filing time
11 Feb 2022, 17:09:59 UTC
Previous filing
15 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TPTX Common Stock Sale $8,022 -221 -0.99% $36.30 22,078 09 Feb 2022 Direct F1, F2
transaction TPTX Common Stock Award $0 +16,283 +74% $0.000000 38,361 09 Feb 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TPTX Stock Option (right to buy) Award $0 +58,600 $0.000000 58,600 09 Feb 2022 Common Stock 58,600 $37.68 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021.
F2 The Reporting Person acquired 199 shares on June 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 333 shares on December 10, 2021 pursuant to the ESPP.
F3 Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan.
F4 1/48th of the shares vest monthly following February 9, 2022.